Daan D Wisselink1, Linde L F Braakhuis2, Gaetano Gallo3, Wilhelmina M U van Grevenstein4, Susan van Dieren5, Niels F M Kok6, Philip R de Reuver7, Pieter J Tanis8, Ignace H J T de Hingh9. 1. Department of Surgery, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, the Netherlands. Electronic address: d.d.wisselink@amc.uva.nl. 2. Department of Surgery, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, the Netherlands. Electronic address: l.l.braakhuis@amc.uva.nl. 3. Department of Medical and Surgical Sciences, Università Magna Graecia di Catanzaro, Viale Europa, 88100 Catanzaro, CZ, Italy. Electronic address: gaetanogallo1988@gmail.com. 4. Department of surgery, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands. Electronic address: W.M.U.vanGrevenstein@umcutrecht.nl. 5. Clinical Research Unit, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, the Netherlands. Electronic address: s.vandieren@amc.uva.nl. 6. Department of surgery, Antoni van Leeuwenhoek hospital, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands. Electronic address: n.kok@nki.nl. 7. Department of surgery, Radboud University Medical Centre, Geert Grooteplein-Zuid 22, 6525 GA Nijmegen, the Netherlands. Electronic address: Philip.deReuver@radboudumc.nl. 8. Department of Surgery, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, the Netherlands. Electronic address: p.j.tanis@amsterdamumc.nl. 9. Department of surgery, Catharina hospital, Michelangelolaan 2, 5623 EJ Eindhoven, the Netherlands. Electronic address: Ignace.d.hingh@catharinaziekenhuis.nl.
Abstract
BACKGROUND: The role of hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin in addition to cytoreductive surgery (CRS) has recently been questioned in peritoneal metastases of colorectal cancer. Whether this applies to all published CRS/HIPEC regimens is unclear. METHODS: A systematic literature search identified 46 studies on CRS/HIPEC using either oxaliplatin of mitomycin C with at least one oncological outcome parameter RESULTS: Oxaliplatin and mitomycin C studies were comparable regarding extent of disease, but differed substantially regarding synchronous versus metachronous presentation, application of neo-adjuvant systemic chemotherapy, duration of HIPEC, and completeness of cytoreduction for at least one of the oncological endpoints. Severe postoperative complication rate seemed significantly higher after oxaliplatin-based CRS/HIPEC. CONCLUSION: Published cohorts on oxaliplatin-based CRS/HIPEC differed essentially from MMC-based procedures, especially considering the application of oxaliplatin-containing neo-adjuvant systemic therapy and shorter exposure time to intraperitoneal chemotherapy in oxaliplatin studies. No meaningful comparison could be made regarding DFS and OS.
BACKGROUND: The role of hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin in addition to cytoreductive surgery (CRS) has recently been questioned in peritoneal metastases of colorectal cancer. Whether this applies to all published CRS/HIPEC regimens is unclear. METHODS: A systematic literature search identified 46 studies on CRS/HIPEC using either oxaliplatin of mitomycin C with at least one oncological outcome parameter RESULTS:Oxaliplatin and mitomycin C studies were comparable regarding extent of disease, but differed substantially regarding synchronous versus metachronous presentation, application of neo-adjuvant systemic chemotherapy, duration of HIPEC, and completeness of cytoreduction for at least one of the oncological endpoints. Severe postoperative complication rate seemed significantly higher after oxaliplatin-based CRS/HIPEC. CONCLUSION: Published cohorts on oxaliplatin-based CRS/HIPEC differed essentially from MMC-based procedures, especially considering the application of oxaliplatin-containing neo-adjuvant systemic therapy and shorter exposure time to intraperitoneal chemotherapy in oxaliplatin studies. No meaningful comparison could be made regarding DFS and OS.
Authors: Francesco Santullo; Carlo Abatini; Miriam Attalla El Halabieh; Federica Ferracci; Claudio Lodoli; Lorenzo Barberis; Francesco Giovinazzo; Andrea Di Giorgio; Fabio Pacelli Journal: Front Surg Date: 2022-05-18
Authors: Roxan F C P A Helderman; Daan R Löke; Jan Verhoeff; Hans M Rodermond; Gregor G W van Bochove; Menno Boon; Sanne van Kesteren; Juan J Garcia Vallejo; H Petra Kok; Pieter J Tanis; Nicolaas A P Franken; Johannes Crezee; Arlene L Oei Journal: Cells Date: 2020-07-25 Impact factor: 6.600
Authors: Job P van Kooten; Nadine L de Boer; Marjolein Diepeveen; Cornelis Verhoef; Jacobus W A Burger; Alexandra R M Brandt-Kerkhof; Eva V E Madsen Journal: Pleura Peritoneum Date: 2021-03-24